

Section 1332 of the Patient Protection and Affordable Care Act (PPACA) State Innovation Waivers – Reinsurance Waiver Pass-through Funding Report

Reporting Instructions: Please capture data for the 1332 waiver grant yearly pass-through funding report in this template, which has been developed based on your specific terms and conditions and in accordance with PPACA section 1332(a)(3). Pass-through funding reports are due yearly throughout the life of your waiver no later than September 15 of the current calendar year in order to inform pass-through funding calculations for the following calendar year. The pass-through funding amount will be reported to the state as soon as practicable, conditional on timely receipt of this report.

STATE:

A. GRANTEE INFORMATION			
1. Reporting Period End Date	2. Report Due Date	3. Date Submitted	
4. Federal Agency and Organization Element to Which Report is Submitted Consumer Information & Insurance Oversight (CCIO)	5. Federal Grant Number Assigned by Federal Agency	6a. DUNS Number	6b. EIN
7. Recipient Organization Name			
Address Line 1			
Address Line 2			
Address Line 3			
City	State	Zip Code	Zip Extension
9. Grant Period End Date		8. Grant Period Start Date	
10. Other Attachments (attach other documents as needed or as instructed by the awarding Federal agency)			

Section 1332 of the Patient Protection and Affordable Care Act (PPACA) State Innovation Waivers – Reinsurance Waiver Pass-through Funding Report

B. PASS-THROUGH FUNDING DATA		
11a. Under section 1332(a)(3), metrics to assist the Departments in calculating pass-through funding for the effective plan year.		
	Value	Comments (if applicable)
i. The final 2021 second lowest cost silver plan (SLCSP) rates for a representative individual (e.g., a 21-year old non-smoker) in each rating area or service area (if premiums vary by geographies smaller than rating areas).	[Please complete as part of the spreadsheet.]	[Please complete as part of the spreadsheet.]
ii. Estimate of what the final 2021 SLCSP rates for a representative individual in each rating area would have been absent approval of this waiver.	[Please complete as part of the spreadsheet.]	[Please complete as part of the spreadsheet.]
iii. The 2020 SLCSP rates for a representative individual in each rating area or service area (if premiums vary by geographies smaller than rating areas). Note that the rating or service area data for 2020 and 2021 needs to be the same, so please use the 2021 service areas for both years of data.	[Please complete as part of the spreadsheet.]	[Please complete as part of the spreadsheet.]
iv. The total amount of all premiums expected to be paid in the non-group market for the 2021 plan year.		
v. Estimate of what total premiums would have been for the 2021 plan year without the waiver.		
vi. The amount of advance premium tax credit (APTC) paid by month and rating area for the current 2020 plan year to date.	[Please complete as part of the spreadsheet provided to SBE states only.]	[Please complete as part of the spreadsheet provided to SBE states only.]
vii. The number of APTC recipients by month and rating area for the current 2020 plan year to date. In addition, the state should provide the state specific age curve premium variation for the current and upcoming plan year;	[Please complete as part of the spreadsheet provided to SBE states only.]	[Please complete as part of the spreadsheet provided to SBE states only.]

Section 1332 of the Patient Protection and Affordable Care Act (PPACA) State Innovation Waivers – Reinsurance Waiver Pass-through Funding Report

viii. Estimate of total reinsurance reimbursements for the 2021 reporting year.		
ix. Estimate of total 2021 enrollment for the market.		
x. Estimate of what total 2021 enrollment for the market would be without the waiver		
11b. Under section 1332(a)(3), a narrative to explain the methodology used to estimate data to assist the Departments in calculating pass-through funding for the subsequent year.		
	Narrative	
i. For the estimate of what the final SLCS rates for a representative individual in each rating area would have been in 2021 without the waiver, provide a narrative that includes information on the methods and assumptions used to estimate this data.		
ii. For the estimate of what total premiums would have been for the plan year (2021) without the waiver, provide a narrative that includes information on the methods and assumptions used to estimate this data.		
iii. An explanation on why the experience for the reporting year (2021) may vary from previous estimates and how assumptions used to estimate the impact have changed. This includes an explanation for changes in the estimated impact of the waiver on aggregate premiums, the estimated impact to the SLCS rates, and the estimated impact on enrollment. The state should also explain changes to the estimated reinsurance estimates relative to prior estimates.		